NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Medical Devices · USD

Co-Diagnostics, Inc. Common Stock (CODX) Stock Analysis

Co-Diagnostics, Inc. Common Stock (CODX) is a Medical Devices stock listed on NASDAQ and quoted in US Dollar.

CODX

$1.16

$0.00 (0.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CODX with… →

CODX Key Statistics

As of Sep 4, 2026
Trading
Open
$1.18
Previous Close
$1.16
Day's Range
1.14–1.19
52-Week Range
0.94–46.50
Volume
60.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.85
Valuation
Market Cap
$8.10M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
11.23
EPS (ttm)Profit attributable to each share over the last twelve months.
−25.89
Financials (FY)
Revenue (FY)
$622.49K−84.10%
Net Income (FY)
−$46.90M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
6.98M
1-Year Return
−87.49%
Dividend and dates
Earnings Date
November 16, 2026
Avg Volume
458.37K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CODX Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−77.12%
2025−77.47%
2024−43.61%
2023−47.22%
2022−71.78%
2021−3.98%
2020+939.11%
2019−39.93%
2018−43.56%
2017 (partial year)−54.56%

As of September 4, 2026.

CODX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$622.49K−$46.90M−7533.6%
2024$3.92M−$37.64M−961.4%
2023$6.81M−$35.33M−518.7%
2022$34.22M−$14.24M−41.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$622.49K$400.11K−$31.28M−$46.90M−7533.6%
2024$3.92M$2.92M−$40.08M−$37.64M−961.4%
2023$6.81M$2.63M−$42.71M−$35.33M−518.7%
2022$34.22M$28.74M−$11.59M−$14.24M−41.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CODX Valuation vs Medical Devices Median

Median of 151 stocks
MetricCODXMedical Devices medianvs median
P/S ratio11.232.983.8x the median
Profit margin0.00%−1.69%1.7 pts above

Medians across 151 Medical Devices stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Co-Diagnostics, Inc. Common Stock (CODX) is capitalised at $8.10M on the latest close. It is classified in the Medical Devices industry, within the Healthcare sector. Headcount on file is 115.

CODX last closed at $1.16 on September 4, 2026. The close was unchanged from the previous session. The 52-week range on file runs from $0.94 to $46.50. The latest close sits 23.4% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $622.49K. That is −84.10% against the prior fiscal year, when revenue was $3.92M. The same year closed with a net loss of $46.90M. Profit margin runs at 0%. That is 1.7 percentage points above the Medical Devices median of −1.69%. Trailing earnings per share are −25.89.

Across the 4 fiscal years on file, revenue moves from $34.22M in 2022 to $622.49K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 11.23. On price-to-sales that is 3.8 times the Medical Devices median of 2.98. The medians here are taken across 151 Medical Devices companies that report the metric.

Over the trailing twelve months the price has returned −87.49%. Across 5 years the annualized return works out at −67.55%. The reported beta is 2.86. Annualized volatility over the trailing 9 years is 171.34%.

Growth & Income

No dividend is on file for CODX.

The strongest complete calendar year on file is 2020 at +939.11%; the weakest is 2025 at −77.47%. Of the 8 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −77.12% year to date.

Peer Comparison

Co-Diagnostics, Inc. Common Stock (CODX) operates in the Medical Devices industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Co-Diagnostics, Inc. Common Stock CODX $8.10M —
Abbott Laboratories ABT $187.45B 35.1
Medtronic plc. MDT $120.46B 22.9
Stryker Corporation SYK $116.27B 31.9

The Medical Devices industry average P/E ratio is 26.8x. Co-Diagnostics, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Medical Devices Stocks

ABT

Abbott Laboratories

$187.45B

 MDT

Medtronic plc.

$120.46B

 SYK

Stryker Corporation

$116.27B

 BSX

Boston Scientific Corporation

$69.27B

 EW

Edwards Lifesciences Corporation

$51.82B

 DXCM

DexCom, Inc.

$33.17B
View all Medical Devices stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Co-Diagnostics, Inc. Common Stock

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.

Visit website →